Clinical Collaboration and Licensing Agreement between Adaptimmune and Galapagos for Groundbreaking Cancer Therapy
Thursday, 30 May 2024, 17:12
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement
Description: Adaptimmune and Galapagos have entered into a clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, for treating head and neck cancer.
Key Highlights:
- Partnership Impact: The collaboration aims to advance innovative cancer treatment options.
- Exclusive Licensing Option: Galapagos has the opportunity to exclusively license uza-cel for head and neck cancer.
The strategic alliance between these biopharmaceutical companies holds the potential to drive significant advancements in cancer therapy, offering new hope to patients.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.